Genetic determinants of 5-lipoxygenase pathway in a Spanish population and their relationship with cardiovascular risk

Atherosclerosis

Volumn 224, Issue 1, 2012, Pages 129-135

  Camacho, Mercedes ^a   Martinez Perez, Angel ^a   Buil, Alfonso ^a   Siguero, Laura ^a   Alcolea, Sonia ^a   López, Sonia ^a   Fontcuberta, Jordi ^a   Souto, Juan Carlos ^a   Vila, Luis ^a   Soria, José Manuel ^a  

^a BIOMEDICAL RESEARCH INSTITUTE SANT PAU IIB SANT PAU   (Spain)

Author keywords

5 lipoxygenase; FLAP; Leukotrienes; LTA4 hydrolase; LTC4 synthase; Thrombosis

Indexed keywords

ARACHIDONATE 5 LIPOXYGENASE; ARACHIDONATE 5 LIPOXYGENASE ACTIVATING PROTEIN; LEUKOTRIENE A4 HYDROLASE; LEUKOTRIENE B4; LEUKOTRIENE C4 SYNTHASE;

ADULT; ARTERY THROMBOSIS; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; ENVIRONMENTAL FACTOR; FATTY ACID BLOOD LEVEL; FEMALE; GENETIC ASSOCIATION; GENETIC CORRELATION; GENETIC SUSCEPTIBILITY; GENETIC TRAIT; HERITABILITY; HOUSEHOLD; HUMAN; HUMAN CELL; HUMAN TISSUE; IDIOPATHIC DISEASE; MAJOR CLINICAL STUDY; MALE; PHENOTYPIC VARIATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; SEX DIFFERENCE; SMOKING; SPAIN; THROMBOPHILIA;

5-LIPOXYGENASE-ACTIVATING PROTEINS; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ARACHIDONATE 5-LIPOXYGENASE; CARDIOVASCULAR DISEASES; CHILD; CHILD, PRESCHOOL; EPOXIDE HYDROLASES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GLUTATHIONE TRANSFERASE; HUMANS; LEUKOTRIENE B4; MALE; MIDDLE AGED; PHENOTYPE; RISK FACTORS; SPAIN; THROMBOPHILIA;

EID: 84865362606     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2012.07.001     Document Type: Article

References (30)

1. Vila L. Cyclooxygenase and 5-lipoxygenase pathways in the vessel wall: role in atherosclerosis. Med Res Rev 2004, 24:399-424.
2. Riccioni G., Zanasi A., Vitulano N., Mancini B., D'Orazio N. Leukotrienes in atherosclerosis: new target insights and future therapy perspectives. Mediators Inflamm 2009, 2009. 737282.
3. Ford-Hutchinson A.W., Bray M.A., Doig M.V., Shipley M.E., Smith M.J., Leukotriene B. A potent chemokinetic and aggregating substance released from polymorphonuclear leukocytes. Nature 1980, 286:264-265.
4. Lee E., Lindo T., Jackson N., et al. Reversal of human neutrophil survival by leukotriene B(4) receptor blockade and 5-lipoxygenase and 5-lipoxygenase activating protein inhibitors. Am J Respir Crit Care Med 1999, 160:2079-2085.
5. 4 hydrolase in human atherosclerotic lesions correlates with symptoms of plaque instability. Proc Natl Acad Sci U S A 2006, 103:8161-8166.
6. Aiello R.J., Bourassa P.-A., Lindsey S., Weng W., Freeman A., Showell H.J. Leukotriene B4 receptor antagonism reduces monocytic foam cells in mice. Arterioscler Thromb Vasc Biol 2002, 22:443-449.
7. Zhao L., Moos M.P.W., Gräbner R., et al. The 5-lipoxygenase pathway promotes pathogenesis of hyperlipidemia-dependent aortic aneurysm. Nat Med 2004, 10:966-973.
8. Bäck M., Bu D., Bränström R., Sheikine Y., Yan Z.-Q., Hansson G.K. Leukotriene B4 signaling through NF-κB-dependent BLT1 receptors on vascular smooth muscle cells in atherosclerosis and intimal hyperplasia. Proc Natl Acad Sci U S A 2005, 102:17501-17506.
9. 4 and BLT1 in smooth muscle cell recruitment. Circulation 2005, 112:578-586.
10. Houard X., Ollivier V., Louedec L., Michel J.B., Bäck M. Differential inflammatory activity across human abdominal aortic aneurysms reveals neutrophil-derived leukotriene B4 as a major chemotactic factor released from the intraluminal thrombus. FASEB J 2009, 23:1376-1383.
11. In K.H., Asano K., Beier D., et al. Naturally occurring mutations in the human 5-lipoxygenase gene promoter that modify transcription factor binding and reporter gene transcription. J Clin Invest 1997, 99:1130-1137.
12. Dwyer J.H., Allayee H., Dwyer K.M., et al. Arachidonate 5-lipoxygenase promoter genotype, dietary arachidonic acid, and atherosclerosis. N Engl J Med 2004, 350:29-37.
13. Assimes T.L., Knowles J.W., Priest J.R., et al. Common polymorphisms of ALOX5 and ALOX5AP and risk of coronary artery disease. Hum Genet 2008, 123:399-408.
14. González P., Reguero J.R., Lozano I., Morís C., Coto E. A functional Sp1/Egr1-tandem repeats polymorphism in the 5-lipoxygenase gene is not associated with myocardial infarction. Int J Immunogenet 2007, 34:127-130.
15. Helgadottir A., Manolescu A., Thorleifsson G., et al. Stefansson K the gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke. Nat Genet 2004, 36:233-239.
16. Bäck M. Inhibitors of the 5-lipoxygenase pathway in atherosclerosis. Curr Pharm Des 2009, 15:3116-3132.
17. Helgadottir A., Manolescu A., Helgason A., et al. A variant of the gene encoding leukotriene A4 hydrolase confers ethnicity-specific risk of myocardial infarction. Nat Genet 2006, 38:68-74.
18. Yamada Y., Kato K., Oguri M., et al. Association of genetic variants with atherothrombotic cerebral infarction in Japanese individuals with metabolic syndrome. Int J Mol Med 2008, 21:801-808.
19. Lovannisci D.M., Lammer E.J., Steiner L., et al. Association between a leukotriene C4 synthase gene promoter polymorphism and coronary artery calcium in young women: the Muscatine study. Arterioscler Thromb Vasc Biol 2007, 27:394-399.
20. Bevan S., Dichgans M., Wiechmann H.E., Gschwendtner A., Meitinger T., Markus H.S. Genetic variation in members of the leukotriene biosynthesis pathway confers an increased risk of ischemic stroke: a replication study in two independent populations. Stroke 2008, 39:1109-1114.
21. 4 synthase and risk of ischemic cerebrovascular disease. Arterioscler Thromb Vasc Biol 2008, 28:990-996.
22. Soria J.M., Almasy L., Souto J.C., et al. A genome search for genetic determinants that influence plasma fibrinogen levels. Arterioscler Thromb Vasc Biol 2005, 25:1287-1292.
23. Buil A., Soria J.M., Souto J.C., et al. Protein C levels are regulated by a quantitative trait locus on chromosome 16: results from the genetic analysis of idiopathic thrombophilia (GAIT) project. Artherioscler Thromb Vasc Biol 2004, 24:1321-1325.
24. Blangero J., Almasy L. Multipoint oligogenic linkage analysis of quantitative traits. Genet Epidemiol 1997, 14:959-964.
25. Almasy L., Blangero J. Multipoint quantitative trait linkage analysis in general pedigrees. Am J Hum Genet 1998, 62:1198-1211.
26. 2 biosynthetic machinery in a spanish population. Arterioscler Thromb Vasc Biol 2010, 30:128-134.
27. Jawien J., Gajda M., Olszanecki R., Korbut R. BAY X 1005 attenuates atherosclerosis in apoE/LDLR-double knockout mice. J Physiol Pharmacol 2007, 58:583-588.
28. Agnelli G., Becattini C. Venous thromboembolism and atherosclerosis: common denominators or different diseases?. J Thromb Haemostasis 2006, 4:1886-1890.
29. Poredos P., Jezovnik M.K. The role of inflammation in venous thromboembolism and the link between arterial and venous thrombosis. Int Angiol 2007, 26:306-311.
30. Fair A., Pritchard K.A. Oxidized low density lipoprotein increases U937 cell 5-lipoxygenase activity: induction of 5-lipoxygenase activating protein. Biochem Biophys Res Commun 1994, 201:1014-1020.